ライフサイエンスコーパス: rebound

1 nd oxygen of the Fe(III)-OH complex ("oxygen rebound").

2 nced an increase in CD30+ cells before viral rebound.

3 ubstitutions, and were associated with virus rebound.

4 om transfer followed by an immediate radical rebound.

5 xpansions played a significant role in viral rebound.

6 from previous fire may lose their ability to rebound.

7 21*) and Fe(III)-OH HAT products and prevent rebound.

8 t arise quickly within 2-4 weeks after viral rebound.

9 contribution of lymph node viruses to viral rebound.

10 ferryl complex and surprisingly competitive rebound.

11 the rate of HAT but also the rate of ligand rebound.

12 losely related to clinical latency and viral rebound.

13 d a remarkably heterogeneous source of viral rebound.

14 ifying (excluding) comorbidity, or had viral rebound.

15 kyr BP due to glacioisostatic rebound.

16 akes relatively little contribution to viral rebound.

17 Sleep deprivation results in a sleep rebound.

18 on almost invariably results in robust viral rebound.

19 response following cART withdrawal and viral rebound.

20 KO and OE mice exhibited a homeostatic sleep rebound.

21 (PLEX) have limited success due to antibody rebound.

22 ow more accurate prediction of time to viral rebound.

23 before detectable plasma RNA), and after HIV rebound.

24 annel and is necessary for homeostatic sleep rebound.

25 duration, it would be unlikely to prevent a rebound.

26 cure trials by closely monitoring for HIV-1 rebound.

27 esponses might increase efficacy and prevent rebound.

28 ce experienced near-extinction but has since rebounded.

29 after the first year P. aeruginosa densities rebounded.

30 n winning percentage, shooting accuracy, and rebounding.

31 Of the 4519 viral rebounds, 3105 (69%) were defined by measurement of a si

32 slab so rapid that it caused a viscoelastic rebound across the whole of Japan.

33 re RYGB quit pre-surgery, smoking prevalence rebounded across 7-years, primarily due to relapse.

34 Overall, only two dropouts (one rebound activity and one gastrointestinal side effect) w

35 cm vs placebo, 5.05 cm; P = .01) and insulin rebound (aFMT, -1.46 +/- 3.6 muIU/mL vs placebo, 1.64 +/

36 Here, we demonstrate that the rapid rebound after alloSCT was related to a highly replicativ

37 cted cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assess

38 table effect on the viral reservoir or viral rebound after ART discontinuation.

39 ilent genomes in M s can contribute to viral rebound after ART interruption and should be considered

40 rvoirs in lymphoid tissues and delayed HIV-1 rebound after cART cessation in the HIV-1-infected hu-mi

41 e studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART)

42 etent reservoir (RCR) that can predict viral rebound after combined antiretroviral treatment (cART) i

43 py (cART), CPT31 monotherapy prevented viral rebound after discontinuation of cART.

44 tem's systemic resilience and its ability to rebound after large-scale population loss.

45 antibiotics and restricts pulmonary disease rebound after premature (nonsterilizing) antibiotic cess

46 limits lung pathology, and restricts disease rebound after premature antibiotic cessation.

47 atropine with regard to myopic progression, rebound after treatment cessation, and minimization of s

48 eservoir for SIV and may contribute to viral rebound after treatment interruption.

49 f the latent reservoir and the time to HIV-1 rebound after treatment interruption.

50 Although there are reports of myopic rebound after treatment is discontinued, this seems to b

51 system, as demonstrated by the lack of viral rebound after withdrawal of treatments, and by adoptive

52 Furthermore, virus rebounded after treatment interruption to similar levels

53 Basophil AUC rebounds after avoidance in subjects with TD.

54 sizes of the reservoirs from which infection rebounds after treatment interruption.

55 icted V1 loop interference have faster virus rebound and a lower maximum decrease in plasma viremia,

56 nterference are associated with faster virus rebound and a smaller decrease in the plasma virus level

57 ndodomain were insufficient to prevent viral rebound and CD4(+) T cell loss after the discontinuation

58 n PLWH on ART could contribute to control of rebound and could be targeted for boosting in curative s

59 lation or radical diffusion (known as the OH-rebound and dissociation mechanisms) following H-atom ab

60 ) and up to 76 weeks (patients with no viral rebound and excluding those who were randomised to the p

61 iduals, yet VRC01 infusions modestly delayed rebound and participants who showed a faster decay of VR

62 which upon ART interruption results in viral rebound and pathogenesis.

63 rate-cofactor disposition to disfavor oxygen rebound and permit halogen coupling to prevail.

64 is therefore important for preventing viral rebound and potential complications such as antiviral re

65 O-C-H...H critical geometries, which produce rebound and stripping mechanisms, respectively.

66 3,210) but was associated with renewed viral rebound and switch.

67 to baloxavir and were associated with virus rebound and variable clinical response in clinical trial

68 ereas traveling in general reduces offensive rebounding and increases the number of points the opposi

69 vity, and then, following the CS, a pause, a rebound, and finally a late inhibition of SS activity fo

70 , to determine factors associated with viral rebound, and to use these estimates to predict long-term

71 during ART suppression, and following viral rebound, and we compare rebound viral RNA after ART disc

72 After the drug was discontinued, parasitism rebounded, and immunopathology recurred.

73 ne dissipated within a few days and bacteria rebounded, approaching preflush concentrations after 6-7

74 Children reaching this adiposity rebound (AR) early are at risk for adult obesity.

75 ydrogen atom abstraction followed by radical rebound, as observed in the native C-H hydroxylation mec

76 Viral rebound at or before week 12 was associated with the app

77 ncing data presented compartmentalized viral rebound between blood and semen in one HIV coding region

78 rrent injection or hyperpolarization-induced rebound burst firing of nRT neurons.

79 : 1) a prolonged hyperpolarization preceding rebound bursts, accompanied by a hyperpolarizing shift i

80 richness and further delayed a biodiversity rebound by at least 35 million years.

81 -19 will decrease temporarily during summer, rebound by autumn, and peak next winter.

82 6-hour treatments with MAPK inhibitors, but rebounded by 24 hours, suggesting the presence of resist

83 propose that the apparent ultrafast radical rebound can be explained by a mechanism in which C-H abs

84 Rebound can occur after discontinuation or change to alt

85 alloBMT was safe, but life-threatening viral rebound can occur with ART interruption.

86 immune responses, but delayed time to viral rebound compared to that in placebo recipients by only s

87 t proviruses were found to contribute to the rebound compartment by recombination.

88 rrently a need for proxy measures of the HIV rebound competent reservoir (RCR) that can predict viral

89 proportion of participants with virological rebound (confirmed viral load >/=50 copies per mL or pre

90 ould be limited to short-term use to prevent rebound congestion, in limited circumstances, patients r

91 tes, we show that reactions following the OH-rebound coordinate concentrate the RM kinetic energy on

92 r, it is unknown whether FND itself causes a rebound corneal neovascularisation and whether that can

93 mate relevant biological parameters from SIV rebound data.

94 The rate of first viral rebound declined substantially over time until 7 years f

95 macological block of IA completely abolished rebound delays and, importantly, shortened synaptically

96 kers, and help identify PLWH with long viral rebound delays.

97 Our results showed that viremia rebounded despite the absence of HIV-1 adaptation to VRC

98 s (HIV) infection that increase before viral rebound during analytical treatment interruption (ATI) m

99 One participant had a viral rebound during follow-up with hepatic decompensation and

100 ting the elastic tendency of the membrane to rebound during protein polymerization and depolymerizati

101 by accounting for heterogeneity in infection rebound dynamics, and determine a recrudescence rate of

102 progression after cessation of treatment, a rebound effect was noted.

103 overall sales and did not lead to detectable rebound effects: Vegetarian sales were not lower at othe

104 ese BD2-selective inhibitors demonstrated no rebound expression effects.

105 Rebound firing, which can have unwanted effects on neura

106 to achieve HIV-1 remission and prevent viral rebound following analytical treatment interruption (ATI

107 Historical data regarding time to viral rebound following analytical treatment interruption (ATI

108 Viral rebound following antiretroviral therapy (ART) discontin

109 e effectively and safely or to prevent viral rebound following ART cessation.

110 may contribute to viral blips during ART or rebound following ART interruption.IMPORTANCE A reason t

111 RT to determine the kinetics of plasma viral rebound following ATI.

112 ss viral replication, and delay plasma viral rebound following discontinuation of antiretroviral ther

113 tence of viral reservoirs that lead to viral rebound following discontinuation of antiretroviral ther

114 mphoid tissue as a potential source of HIV-1 rebound following interruption of antiretroviral therapy

115 d at the viral DNA level or to prevent virus rebound following therapy interruption in immune system-

116 which can reactivate and contribute to viral rebound following treatment interruption.

117 ite ART, indicated two important sources for rebound following treatment interruption.

118 is process would prevent HIV transmission or rebound from the latent reservoir.

119 is: how long will it be before the biosphere rebounds from our actions?

120 Children experiencing rebound >/=5,000 copies/ml were much less likely to resu

121 iraemia (80-5,000 copies/ml) and 10% with VL rebound >/=5,000 copies/ml.

122 esuppressed <80 copies/ml after confirmed VL rebound >/=5,000 copies/ml.

123 The primary outcome was the time to viral rebound (>=400 copies per milliliter).

124 wth clusters were slower to experience viral rebound (hazard ratio 0.83, P = .011) compared with indi

125 espond or experience donor-specific antibody rebound, highlighting the diversity of the individual pa

126 ere does not seem to be a primary source for rebound HIV, cellular proliferation is an important driv

127 Upon rebound, HIV-1 sequences were indistinguishable from tho

128 A single dose of CyP after alphaCD3 depleted rebounding host T(regs) and resulted in a 43-fold increa

129 recently demonstrated that sleeping on high rebound [HR] mattress toppers induced a continuous and m

130 Most iron-2OG enzymes perform a radical rebound hydroxylation at the site of the H-atom abstract

131 their reactivity toward performing a radical rebound hydroxylation of triphenylmethylradical.

132 rred H-atom and the highest chance to follow rebound hydroxylation.

133 cting clonidine should be avoided because of rebound hypertension, but can be added to control residu

134 he detection limit, nevertheless rapid viral rebound immediately ensues upon treatment interruption.

135 ge and race were associated with virological rebound in 2012-2017.

136 in ADCC-competent antibodies, despite viral rebound in all subjects who underwent the short ATI.

137 Data suggest a rebound in As metabolite proportions after FA cessation;

138 ression is likely the direct origin of viral rebound in chronically SIV-infected rhesus monkeys follo

139 administration to wild-type mice there is a rebound in delta power when they enter normal NREM sleep

140 malaria vectors could presage a catastrophic rebound in disease incidence and mortality.

141 s were associated with increased virological rebound in earlier time periods, while only age and race

142 higher FRs ex vivo and tracked the drop and rebound in ensemble mean FR induced by prolonged monocul

143 offer an important tool to anticipate viral rebound in individuals in clinical studies that include

144 aimed to investigate the rate of first viral rebound in people that have achieved initial suppression

145 There was no evidence of a rebound in platelet activity after drug cessation.

146 Compared to that in blood, HIV RNA rebound in semen occurred significantly later (median of

147 First, we found that HIV RNA rebound in semen occurred significantly later and reache

148 enital compartment might contribute to viral rebound in some people with HIV (PWH) interrupting ART.

149 enital compartment might contribute to viral rebound in some PWH interrupting ART.IMPORTANCE To cure

150 However, a rebound in the cell number was observed after the prolon

151 ent increases in survival for the species to rebound in the face of WNS is unknown.

152 utic vaccination can suppress ART-free viral rebound in the SHIV model.

153 8T/F/M) reduced BXM potency and caused virus rebound in treated patients, although the fitness charac

154 After avoidance, basophil AUC rebounded in subjects with TD but not those with SU (P <

155 nsitivity was similar at diagnosis and after rebound, indicating the lack of selection for VRC01 resi

156 likely reservoir of HIV, vulnerable to viral rebound, inflammation, and clinical changes upon stoppin

157 of the inherent reactivity of the analogous rebound intermediate in both enzymes and related catalys

158 ing to meet the primary end point because of rebound iritis (P < 0.001).

159 e anterior chamber at 2 weeks and absence of rebound iritis with medication discontinuation, was the

160 ribute to human immunodeficiency virus (HIV) rebound is essential for eradication.

161 ding to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint.

162 This delta rebound is reduced in mice lacking PO galanin neurons.

163 be able to continue before developing viral rebound is unknown.

164 s similar to known VRC01-susceptible strains rebounded later.

165 timulation suppresses licking and results in rebound licking after stimulation.

166 in basal ganglia activity through gating- or rebound-like mechanisms.

167 )(OH)(X) (X = Cl, Br) complexes in a radical rebound-like process.

168 ine in core body temperature compared to low rebound [LR] mattress toppers during the initial phase o

169 racterizing the dynamics of short term viral rebounds (<= 60 days).

170 Still, gating or rebound may be possible in other physiological situation

171 Suppression of rebound may thus be generally important for nonhydroxyla

172 intermediate energy, a previously unexpected rebound mechanism contributes significantly to the react

173 The rebound mechanism for alkane hydroxylation was invoked o

174 Polymerization occurs through a halide-rebound mechanism in which the nucleophilic twisted amid

175 This feature, combined with the "fluoride-rebound" mechanism, was translated into a protocol for t

176 appear incompatible with standard gating and rebound models.

177 who showed a faster decay of VRC01 in serum rebounded more rapidly.

178 e cessation of cART usually results in viral rebound, mostly due to the presence of viral reservoirs.

179 s of lesions, we selected a case with severe rebound MS disease activity after natalizumab cessation.

180 nt carbon radical and hydroxo ligand (oxygen rebound) must generally be averted.

181 rapidly reduced viral load by ~2 logs before rebound occurred due to the emergence of drug resistance

182 Viral rebound occurred in 13% of those lost from community clu

183 Viral rebound occurred in all individuals, yet VRC01 infusions

184 Viral rebound occurred in the majority of suppressed animals a

185 heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or sometimes year

186 We show that when viral rebound occurs early relative to the viral load doubling

187 ed because all recipients demonstrated rapid rebound of antibodies, with profound T cell-mediated rej

188 with long-term graft survival showed gradual rebound of donor-specific antibodies and antibody-mediat

189 le intrinsic plasticity is essential for the rebound of firing rates, suggesting that synaptic scalin

190 We predicted a rebound of importations from South East Asia in the succ

191 w detection levels (2-4 ng/L) and subsequent rebound of REE concentrations in regions down-gradient o

192 T(regs), subsequently followed by more rapid rebound of T(regs) Despite robust depletion of host T(co

193 ed to asthenospheric upwelling and isostatic rebound of the plateau region during the late Cretaceous

194 replication-competent SIV and contribute to rebound of the virus after treatment interruption.

195 Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels.

196 man immunodeficiency virus (HIV) and a rapid rebound of virus replication follows analytical treatmen

197 t because only intact proviruses cause viral rebound on ART interruption.

198 ation by these enzymes occurs via a hydroxyl rebound or alkoxide mechanism and highlighted the need t

199 rapeutic interventions on time to viral load rebound or altered viral setpoint.

200 or to PGT121 alone in delaying time to viral rebound or reducing peripheral blood mononuclear cell (P

201 episodes of cerebrospinal fluid (CSF) viral rebound or sustained plasma and CSF viremia during treat

202 etroviral therapy [ART] and at risk of viral rebound) or treatment-naive patients initiating their fi

203 r, the "Berlin patient" remained free of HIV rebound over a decade after stopping cART.

204 day 3 after infection, experienced sustained rebound plasma viraemia when treatment was interrupted.

205 Rebounding plasma HIV-1 sequences were phylogenetically

206 ns.SIGNIFICANCE STATEMENT Our study examines rebound, postburst, and synaptically evoked inhibitory p

207 rates; and (v) reduced spike clustering and rebound potentials.

208 need to consider potential conflicts between rebounding predators or endangered predators and prey.

209 in direct analogy with the elusive radical "rebound" process proposed for nonheme iron enzymes.

210 factor in the selectivity of non-heme iron "rebound" processes.

211 The C21-hydroxylated (rebound) product, which undergoes deprenylation, predomi

212 igrostriatal neurons differ substantially in rebound properties with mesoaccumbal neurons displaying

213 Efforts to model the rebound reaction in a synthetic system have been unsucce

214 The rebound response of a landing mosquito is well-character

215 d either by a concerted pathway or a radical rebound sequence that is faster than C-C bond rotation.

216 overlap between 205 latent reservoir and 125 rebound sequences in the four individuals who underwent

217 wal alters viral dynamics: we found a higher rebound set point but similar peak viral loads compared

218 However, HSSW salinity rebounded sharply after 2014, with values in 2018 simila

219 Subsequently, surface water pH rebounded sharply with the extinction of marine calcifie

220 creases in wakefulness followed by sustained rebound sleep after washout.

221 is, as galn mutants almost completely lacked rebound sleep following both pharmacologically induced n

222 of galn transcripts was predictive of total rebound sleep time.

223 ressing neurons as selectively active during rebound sleep, and the relative induction of galn transc

224 kefulness predicted the amount of subsequent rebound sleep.

225 Antibacterial drug development activity rebounded substantially from 2002 - 2009, primarily led

226 ody-mediated rejection with humoral-response rebound, suggesting desensitization must be maintained a

227 treated and untreated mice after body weight rebound, suggesting that BChE gene transfer did not alte

228 The longer the time to viral rebound, the more efficacious the therapy.

229 l therapy (cART) eventually experience viral rebound, the return of viral loads to pretreatment level

230 et counts had a nadir at day 3 followed by a rebound thrombocytosis at day 21, with nadir values sign

231 ictions on a person living with HIV (PLWH)'s rebound time distribution based on biomarkers, and help

232 ces between pre-ATI and postinterruption pre-rebound time points in percentages of lymphocytes expres

233 We incorporate this information and viral rebound times to parametrize our model.

234 th the time between ART suspension and viral rebound to detectable levels.

235 No study participants had plasma viral rebound to more than 400 copies per milliliter.

236 nt was highly variable and ranged from viral rebound to near pretreatment levels to sustained suppres

237 wo substrate carbons for different outcomes, rebound to the site capable of the alternative outcome s

238 In the absence of ART, plasma virus rebounded to 10(3) vRNA copies/ml by day 10 after IL-2-D

239 However, prevalence rebounded to 9% by PCR two months after conclusion of MD

240 Forty-eight weeks posttreatment, HBV DNA rebounded to baseline levels in all participants, includ

241 Interestingly, c-Jun protein rebounded to normal levels 4 h following U0126 exposure

242 ocular pressure measurements using the ICare rebound tonometer (ICare, Helsinki, Finland) were obtain

243 eal-compensated IOP (IOP(cc)), and the ICare Rebound Tonometer (RBT) (Tiolat, Oy, Helsinki, Finland).

244 glaucoma can perform self-tonometry using a rebound tonometer and examine patient acceptability.

245 On average, IOP by the rebound tonometer was 2.66 mm Hg lower than Goldmann app

246 The IOPs with the rebound tonometer were similar whether obtained by self-

247 d using Goldmann applanation tonometry and a rebound tonometer.

248 associated with increased risk of HIV viral rebound (transitioning from VLS to NVL; 1.50 [1.32-1.69]

249 ssion can cause RNA and protein synthesis to rebound, triggering neuropathogenesis months after acute

250 ssue reservoir and its contribution to viral rebound upon ART interruption are not clear.

251 ral therapy, and likely contributes to viral rebound upon cessation of antiretroviral therapy.

252 ion in the absence of ART but does not delay rebound upon drug removal as XPB rapidly reemerges.

253 Viral rebound upon stopping combined antiretroviral therapy po

254 celerates HIV-1 suppression and delays viral rebound upon treatment interruption.

255 We predicted the probability of rebound using a mathematical model and inference approac

256 (22.9 years, IQR 19.4-25.9) than those with rebound viraemia (20.4 years, 18.8-22.2), or persistent

257 reflecting sustained suppression (31 [30%]), rebound viraemia (55 [53%]), and persistent viraemia (18

258 and following viral rebound, and we compare rebound viral RNA after ART discontinuation with near fu

259 ective antiretroviral therapy (ART) can fuel rebound viremia after ART interruption and is a central

260 ing antiretroviral [ART] therapy; n = 2 with rebound viremia after stopping ART), who provided serial

261 and production of progeny capable of causing rebound viremia following treatment interruption.

262 antiretroviral therapy and that can lead to rebound viremia if antiviral therapy is removed is criti

263 ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-li

264 ent reservoir in resting CD4(+) T cells, and rebound viremia occurs following treatment interruption.

265 infected viral reservoir that gives rise to rebound viremia upon cessation of ART.

266 In the absence of ART, these mice developed rebound viremia which, 2 weeks after PBMC injection, was

267 within the CNS, which may eventually lead to rebound viremia.

268 bination may play a role in the emergence of rebound viremia.IMPORTANCE HIV-1 persists as a latent in

269 ART and that M-tropic variants can appear in rebounding viremia when treatment is interrupted.

270 a cogent explanation for differences between rebound virus and viruses detected in standard QVOAs.

271 Recent studies have suggested that rebound virus does not originate directly from individua

272 However, the origin and nature of the rebound virus has remained unclear.

273 Here we evaluate the origin of rebound virus in 16 ART-suppressed, chronically SIV-infe

274 Recombinant viruses are rare in the initial rebound virus populations but arise quickly within 2-4 w

275 ogenetic analyses suggest that the origin of rebound virus was distinct from the viruses identified p

276 es did not appear to be the direct origin of rebound virus.

277 ablished a phylogenetic relationship between rebound viruses and viruses growing out in vitro in the

278 Sequences of initial rebound viruses closely match viral DNA sequences in PBM

279 However, rebound viruses could be accounted for by recombination.

280 to treatment interruption often differ from rebound viruses.

281 To unravel the source of rebounding viruses, we conducted a large-scale HIV-STAR

282 Viral rebound was defined as the first single viral load of mo

283 No viral rebound was observed in the plasma of 67% of the ART-tre

284 nically HLA-sensitized patients; however, Ab rebound was observed over several weeks to months follow

285 nimals ( approximately 33%), a delayed viral rebound was observed that is consistent with the establi

286 ivo; after ART treatment interruption, viral rebound was significantly delayed compared with controls

287 the first available time points after viral rebound, we sequenced HIV-1 env (C2-V3), gag (p24), and

288 tive viral loads >1000 copies/mL), and viral rebound were compared between participants in strata of

289 tment-experienced patients at risk for viral rebound were randomized to treatment as usual (TAU) or A

290 modern ART does not alter kinetics of viral rebound when compared to previous regimens and that immu

291 However, the epidemic could rebound when such measures are relaxed, possibly leading

292 impact force of cotton yarn with negligible rebound when used for impact reduction applications.

293 treatment interruption, since virus rapidly rebounds when XPB reemerges; however, SP alone without A

294 ting accuracy (i.e., movement precision) and rebounding, which may be separately influenced by either

295 diffuse tenderness without mass, guarding or rebound while reminder of physical exam was unremarkable

296 One patient stopped ART and developed HIV rebound with grade 4 meningoencephalitis at day 146.

297 e investigated factors associated with viral rebound with Poisson regression.

298 nd establishment of viral latency, and viral rebound with return to pretreatment set point viremia fo

299 ed ART and remained aviremic for 7.4 months, rebounding with HIV RNA of 36 copies/mL that rose to 59,

300 ere is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks